10-Q: Nutriband Inc. Q1 2026 Results Show Revenue Decline

Nutriband Inc. reported a decrease in revenue for the first quarter of fiscal year 2026, primarily due to a major customer relocating operations, while also noting a reduction in net loss compared to the prior year.

Summary

• Nutriband Inc. reported revenue of $433,399 for the three months ended April 30, 2026, a decrease from $667,432 in the same period of 2025.
• The net loss for the quarter was $1,241,956, an improvement from a net loss of $1,388,869 in the prior year's quarter.
• The company's cash and cash equivalents stood at $4,006,184 as of April 30, 2026, with working capital of $3,544,125.
• Selling, general, and administrative expenses increased to $1,203,891 from $982,052 in the prior year's quarter.
• Research and development expenses decreased significantly to $247,261 from $683,426, primarily due to reduced labor costs.
• The company continues to focus on the development of its Aversa abuse deterrent transdermal technology, with Aversa Fentanyl as its lead product.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant revenue decline and ongoing operational losses, despite a reduction in the net loss.

Positives

• Reduced net loss by approximately 10.6% to $1,241,956 for the quarter compared to $1,388,869 in the prior year.
• Improved gross margin due to a higher margin sales mix.
• Sufficient cash and cash equivalents of $4,006,184 and working capital of $3,544,125 as of April 30, 2026, supporting operations.
• Management believes operations will be funded for at least one year, alleviating going concern uncertainty.

Negatives

• Revenue decreased by 35.1% to $433,399 for the quarter compared to $667,432 in the prior year.
• The decrease in revenue is attributed to a principal customer relocating operations to Asia, with further demand decrease expected.
• Selling, general, and administrative expenses increased by 22.6% to $1,203,891 from $982,052.
• No revenue was generated from the 4P Therapeutics segment due to a shift in focus and the winding down of a major contract.

Risks

• The company is in the early stages of operations and has incurred substantial losses, with no assurance of achieving profitability or positive cash flow.
• The lead product, Aversa Fentanyl, is still under development and has not yet received FDA approval for marketing in the United States.
• Future success depends on keeping pace with rapid technological changes in the drug delivery industry.
• The company faces risks related to obtaining necessary funding, the success of clinical trials, and FDA approval processes.
• Potential product liability claims and adverse events could negatively impact the business.
• The company is involved in a lawsuit with Joseph Gunnar, LLC and Lucosky Brookman LLP, seeking over $500,000 in damages.
• Economic uncertainties, including geopolitical events and current administration policies, could affect costs, timing of product approvals, and profitability.
• Inflationary factors may increase costs for products, rights, and overhead.

Future Outlook

The company's primary focus remains on the development of its Aversa abuse deterrent transdermal technology, with Aversa Fentanyl as its lead product. The company anticipates further demand decreases in the Pocono Pharmaceuticals segment for the balance of the current year due to a customer's relocation. Management believes it has sufficient funds to operate for at least one year from the filing date, alleviating going concern uncertainty.

Management Comments

• Management believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company's ability to continue operations as a going concern.
• The decrease in revenue from the Pocono Pharmaceuticals segment is due to one of the Company's principal customers moving their operations to Asia. A decrease in demand is expected in the balance of the current year.
• The increase in gross margin is due primarily to higher margins in our sales mix.

Industry Context

StockSavvy.ai notes that Nutriband Inc.'s Q1 2026 results reflect challenges common to early-stage pharmaceutical development companies, particularly in managing revenue fluctuations and R&D expenses. The decline in revenue from the Pocono Pharmaceuticals segment due to customer relocation highlights the sensitivity of contract manufacturing operations to client-specific events. The company's continued investment in its Aversa technology positions it within the growing market for abuse-deterrent drug delivery systems, a critical area given the ongoing opioid crisis.

Comparison to Industry Standards

• Compared to larger pharmaceutical companies with approved products, Nutriband's revenue of $433,399 for the quarter is significantly lower, reflecting its pre-commercialization stage.
• The net loss of $1,241,956 is substantial but represents an improvement over the prior year, indicating progress in cost management relative to revenue generation, a common challenge for R&D-intensive biotech firms.
• The company's R&D spending of $247,261, while reduced from the prior year, is still a significant portion of its expenses, aligning with industry standards for companies developing novel drug delivery technologies.
• The focus on abuse-deterrent technology places Nutriband in a niche within the broader pharmaceutical market, competing with other companies developing similar solutions, though specific direct competitors are not named in this filing.

Legal Proceedings

• Nutriband Inc. is a defendant in a lawsuit filed by Joseph Gunnar, LLC and Lucosky Brookman LLP in the Supreme Court of the State of New York, alleging breach of contract, fraudulent activities, and tortious interference. Gunnar is seeking over $500,000 in damages plus punitive damages, and LB is demanding reimbursement of legal fees.
• Nutriband denies all allegations, claiming the engagement letter was unenforceable and its termination was justified. The company has filed counterclaims against Joseph Gunnar & Co. for intentional interference and breach of fiduciary duty, seeking $1,000,000 for each claim.
• The case is currently in the discovery stage, with no pending hearings or motions. A settlement offer of $100,000 was proposed by the plaintiffs in early 2024, to which the company has not responded.

Related Party Transactions

• During the three months ended April 30, 2026, a director and a related party were issued warrants to purchase 206,080 shares of common stock at an exercise price of $3.73 per share.
• On March 17, 2023, the Company entered into a Credit Line Note agreement for a $5,000,000 credit line facility with a related party, amended on July 17, 2023. Advances bear interest at 7% per annum and were due March 19, 2026. As of April 30, 2026, and January 31, 2026, the balance due was $0.

Stakeholder Impact

• Shareholders may experience dilution from future equity offerings and the exercise of outstanding stock options and warrants.
• The ongoing legal proceedings could result in substantial costs and divert management's attention and resources.
• The company's ability to secure future funding is critical for continued operations and product development, impacting investor confidence.

Next Steps

• Continue development of Aversa Fentanyl and other Aversa-based transdermal products.
• Seek FDA approval for transdermal pharmaceutical products.
• Manage expenses and operations to ensure funding for at least one year.
• Address the ongoing lawsuit with Joseph Gunnar, LLC and Lucosky Brookman LLP.

Key Dates

Recommendation

The company shows progress in reducing its net loss and has a clear development pipeline with its Aversa technology. However, the significant revenue decline, ongoing legal proceedings, and the pre-commercialization status of its lead product warrant a cautious approach. A 'hold' recommendation reflects the potential for future growth balanced against the substantial risks and current financial performance.

Keywords

Nutriband Inc., Form 10-Q, Quarterly Report, Pharmaceuticals, Transdermal Patches, Abuse Deterrent Technology, AVERSA, Fentanyl, Revenue, Net Loss, FDA Approval, Clinical Trials, SEC Filing